StockData

Eli Lilly vs Merck

LLY and MRK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LLY and MRK compare

Eli Lilly is the larger company, worth 3.7 times as much as Merck ($1.3T against $356B).

On earnings, Eli Lilly is cheaper: it trades at 45.9× trailing earnings, against 116× for Merck.

Eli Lilly grew revenue faster over the last twelve months (45.5% versus 4.6% for Merck).

Eli Lilly keeps more of each dollar of sales as profit, with a net margin of 31.9% compared with 4.8% at Merck.

Both pay dividends: Eli Lilly yields 0.37% and Merck 2.4%.

Eli Lilly scores higher on the StockData Score (19 against 9 for Merck), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLLYMRK
Size and price
Market cap$1.3T$356B
Share price$1415.55$144.46
Change, 1 year38.1%55.5%
Change, 5 years444%82.5%
Beta (5Y)0.28−0.14
Employees50K75K
StockData Score
Total score19 (better)9
Valuation score2 (better)0
Growth score5 (better)0
Performance score5 (better)3
Health score4 (better)3
Dividend score33
Valuation
P/E45.9× (better)116×
P/S15.4×5.4× (better)
P/B33.1×8.5× (better)
EV/EBITDA37.3×–
P/FCF–22.2×
PEG0.93 (better)13.70
FCF yield–4.5%
Fair value$1131.93$42.50
Margin of safety−25.1% (better)−240%
Growth
Revenue growth (TTM)45.5% (better)4.6%
Revenue growth, 5Y average21.6% (better)9.4%
Net income growth (TTM)49.8% (better)−80.7%
EPS growth (TTM)50.7% (better)−80.7%
EPS growth, 5Y average27.6% (better)21.2%
Profitability
Gross margin83.6% (better)73.0%
Net margin31.9% (better)4.8%
FCF margin–24.1%
Return on equity86.1% (better)7.0%
Financial health
Debt / equity1.23 (better)1.29
Net debt / EBITDA1.21–
Current ratio1.39 (better)1.32
Altman Z-score8.50 (better)3.71
Piotroski F-score7 (better)4
Dividends and buybacks
Dividend yield0.37%2.4% (better)
Payout ratio21.7%262%
Years of dividend growth915 (better)
Dividend growth, 5Y average15.2% (better)5.8%
Buyback yield0.44%1.2% (better)
Shareholder yield0.81%3.5% (better)
Ownership
Held by institutions83.8%80.3%
Held by insiders10.4%0.05%
Insider net buying, 12 months−$373M−$79.3M (better)
Superinvestors holding34 (better)
Short interest, % of float0.86%1.1%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.